This is a retrospective, non-interventional study of participants with CD and CPAF. This study will assess tumorigenicity risk and all-cause and cancer-specific mortality in participants with darvadstrocel.~The study will enroll approximately 13,080 participants. Data will be collected retrospectively from European secondary data sources. Participants will be assigned to two cohorts:~Darvadstrocel cohort~Matched control cohort: Alternate SoC.~This multi-center trial will be conducted in France, Germany, Netherlands, and Spain. The overall duration of the study will be approximately 96 months, including index period (the time in which eligible participants are included in the study) and 12 months follow-up period.
The main aim is to learn about the risk of cancer after treatment with darvadstrocel compared to other standards of care in people with Crohn's Disease.~In this study, the study doctors will review each participant's past medical records. This study is about collecting existing information only; participants will not receive treatment or need to visit a study doctor during this study.